CORRECTION article

Front. Immunol., 25 July 2025

Sec. Cancer Immunity and Immunotherapy

Volume 16 - 2025 | https://doi.org/10.3389/fimmu.2025.1659836

Correction: Myeloid Zinc Finger 1: insights into its oncogenic potential, prognostic value, and impact on immune microenvironment across cancers

  • 1. Department of Thoracic Surgery, The Affiliated Huaian No.1 People’s Hospital of Nanjing Medical University, Huai’an, China

  • 2. General Surgery Department, Lianshui People’s Hospital Affiliated to Kangda College of Nanjing Medical University, Huai’an, Jiangsu, China

  • 3. Department of Thyroid and Breast Oncological Surgery, Huai’an Second People’s Hospital, The Affiliated Huaian Hospital of Xuzhou Medical University, Huai’an, Jiangsu, China

  • 4. Faculty of Life Science and Food Engineering, Huaiyin Institute of Technology, Huai’an, Jiangsu, China

  • 5. Key Laboratory of Systems Biomedicine, Shanghai Center for Systems Biomedicine, Engineering Research Center of Techniques and Instruments for Diagnosis and Treatment of Congenital Heart Disease, Institute of Developmental and Regenerative Medicine, Xin Hua Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China

  • 6. Department of Oncology, The Affiliated Huaian No.1 People’s Hospital of Nanjing Medical University, Huai’an, China

Author affiliation

In the article, there was an error in the affiliations. “Affiliation 3, Department of Thyroid and Breast Oncological Surgery, Huai’an Second People’s Hospital, The Affiliated Huaian Hospital of Xuzhou Medical University, Huai’an, Jiangsu, China”, was erroneously omitted for author “Aijun Sun”. This affiliation has now been added.

Additionally, author “Aijun Sun” was erroneously assigned to affiliation “2, General Surgery Department, Lianshui People’s Hospital Affiliated to Kangda College of Nanjing Medical University, Huai’an, Jiangsu, China”. This affiliation has now been removed.

The original version of this article has been updated.

Statements

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Summary

Keywords

Myeloid Zinc Finger 1, pan-cancer, tumor immunity, prognostic biomarker, immunotherapy drug susceptibility

Citation

Tian W, Yu C, Xu X, Li J, Peng S, Sun A, Zhang S and Jiang C (2025) Correction: Myeloid Zinc Finger 1: insights into its oncogenic potential, prognostic value, and impact on immune microenvironment across cancers. Front. Immunol. 16:1659836. doi: 10.3389/fimmu.2025.1659836

Received

04 July 2025

Accepted

07 July 2025

Published

25 July 2025

Approved by

Frontiers Editorial Office, Frontiers Media SA, Switzerland

Volume

16 - 2025

Updates

Copyright

*Correspondence: Aijun Sun, ; Shasha Zhang, ; Chao Jiang,

†These authors have contributed equally to this work and share first authorship

Disclaimer

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Outline

Cite article

Copy to clipboard


Export citation file


Share article

Article metrics